Validity and security of leveraging CS1 chimeric antigen receptor T-cell therapy treating relapsed/ refractory/ high risk CS1+ hematological malignancy: a single-center, open, single-arm clinical study

Trial Profile

Validity and security of leveraging CS1 chimeric antigen receptor T-cell therapy treating relapsed/ refractory/ high risk CS1+ hematological malignancy: a single-center, open, single-arm clinical study

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs CD319-chimeric-antigen-T-cell-therapy-Wuhan-Bio-Raid-Biotechnology (Primary)
  • Indications Haematological malignancies
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top